Mefitel film for radiation dermatitis: it works, why not?

Published Date: 13 Mar 2023

According to the results of a phase 3 trial, the use of silicone film before radiotherapy can reduce the incidence of radiodermatitis, so why not use it?

Read Full News

Latest News

FDA Approves First Oral Drug for Dermatomyositis in Adults

The FDA has approved brepocitinib (Lisraya), an oral JAK inhibitor, for the treatment of dermatomyositis, a rare autoimmune disease, in adults.

Early Step-Down Safe, Cost-Effective in Stable Candidiasis

Switching from an echinocandin to an azole within 5 days is not associated with worse outcomes in clinically stable adults with invasive candidiasis, a study shows.

How Safe Is Lifileucel After Patients Go Home?

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

China Approves J&J Psoriasis Pill Icotyde, Says Drugmaker

China's drug regulator has approved Johnson & Johnson's oral pill ⁠for psoriasis, the company said on Thursday, intensifying competition in the ⁠world's second-largest...

Vulvar Lichen Sclerosus Affects 1 in 700 US Women

Vulvar lichen sclerosus shows markedly higher rates in women over 60, with White women experiencing the highest burden, a study shows.

Brepocitinib Controls Skin Disease in Dermatomyositis

Brepocitinib produces rapid and sustained improvements in skin disease, itch, and skin-related quality of life in adults with dermatomyositis.

Todays Updates

Faster 1-Hour MI Rule-Out Is Safe

The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.

Edoxaban Falls Short After Intracranial Hemorrhage in AF

Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.

Drug Benefit Seen in Nonobstructive HCM

A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.

Tailored Approach Shortens Endocarditis Therapy

Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.

Todays Updates

Faster 1-Hour MI Rule-Out Is Safe

The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.

Edoxaban Falls Short After Intracranial Hemorrhage in AF

Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.

Drug Benefit Seen in Nonobstructive HCM

A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.

Tailored Approach Shortens Endocarditis Therapy

Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.

Latest News

The FDA has approved brepocitinib (Lisraya), an oral JAK inhibitor, for the treatment of dermatomyositis, a rare autoimmune disease, in adults.

Switching from an echinocandin to an azole within 5 days is not associated with worse outcomes in clinically stable adults with invasive candidiasis, a study shows.

The T-cell therapy’s inpatient toxicity is well-characterized, but the risks patients may face after hospital discharge have been unclear.

China's drug regulator has approved Johnson & Johnson's oral pill ⁠for psoriasis, the company said on Thursday, intensifying competition in the ⁠world's second-largest...

Vulvar lichen sclerosus shows markedly higher rates in women over 60, with White women experiencing the highest burden, a study shows.

Brepocitinib produces rapid and sustained improvements in skin disease, itch, and skin-related quality of life in adults with dermatomyositis.

News All Time

FDA Staff Unconvinced Drug for Melanoma Shows Benefit

Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting

Fauci's Diaries Released; Cold Brew Recalled; Carly Simon's Diagnosis

Health news and commentary gathered by MedPage Today staff

What Is the 'Barbie Peptide' and Why Is It Risky?

Dermatologists weigh in on the injectable trend

Twice-Rejected Melanoma Drug Gets Love From FDA Panel

Vote at odds with FDA reviewers

Make the Diagnosis: She’s Losing Her Scalp and Eyebrow Hair. Why?

A 51-year-old woman visited her doctor for asymptomatic hair loss on her scalp and eyebrows that she first noticed approximately 5 months prior. Can you diagnose the patient?

FDA Finally OKs Twice-Rejected Melanoma Drug

Approved in combination with nivolumab for patients who progress on prior anti-PD-1 therapy

'Carrot Maxxing' Is a New Name for an Old Trend

Eating lots of carrots can change the color of the skin, but satisfaction may vary

Tanning Is Getting Hot Again. Here's What It Really Does to Your Skin.

Tanning misinformation abounds online

Pebbled Skin and Excessive Hair Growth on a 5-Year-Old's Back

Just two of the multiple symptoms that began to emerge shortly after birth

Can 'Ferritin Face' Signal Underlying Anemia? Hematologists Weigh In

Patients attribute dull skin, brittle hair, and dark under-eye circles to ferritin deficiency

JAK Inhibitor Might Be the Most Effective One Yet for Severe Alopecia

Trials suggest more hair growth with upadacitinib in teens and adults than previously seen

Flight Attendants, Pilots Have Highest Risk of Dying From Radiation-Linked Cancers

Radiation exposure is greater for people flying at high altitudes

4 Deaths Linked to Medical Device; New FDA Chief? Human-Chimp Hybrid Attempt

Health news and commentary gathered by MedPage Today staff

How Much of a Cancer Drug Is Too Much? Some Are Challenging FDA-Approved Dosages.

— Smaller doses of some drugs could save billions and prevent some of the worst side effects

US FDA Approves Regeneron's Rare Bone Disorder Drug

Aug 19 - The U.S. FDA on Wednesday approved Regeneron's drug for a rare genetic disorder ⁠after it significantly reduced abnormal bone formation in certain soft...

Ebola Spreading Exponentially in Congo as Death Toll Tops 2,500, UN Says

More than 2,500 people have now died in the Democratic Republic of Congo's Ebola outbreak, which is spreading exponentially in an area larger ⁠than France, senior United...

Recommended News For You

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

Early Tislelizumab May Boost PFS in Esophageal Cancer

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

Can taking vitamin D supplements every day lower the mortality rate from cancer?

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic Leukemia

Recommended Articles For You

Modern Standards in Oncology and Patient Outcomes 

The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective 

How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies 

Precision Erythropoietic Modeling for Hematologic Disorders 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A study outlines the need for policies that enhance cancer patients' autonomy and information.

2.

Novel biomarker has potential for predicting and treating skin cancer metastasis

3.

PSMA PET: Prostate Cancer Staging Revolution Awaits RCT Data

4.

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

5.

For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.

1.

From Bruises to Blood Clots: Everything You Need to Know about Hematoma 

2.

Understanding Thrombin Time: What It Is and How It Can Help Diagnose Blood Clotting Disorders

3.

Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role

4.

The Latest Causes and Symptoms of Bowen's Disease: All You Need to Know 

5.

Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

2.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

3.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

4.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

5.

From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot